AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
Log in

NYSEAMERICAN:NAVBNavidea Biopharmaceuticals Stock Price, Forecast & News

$3.99
-0.06 (-1.48 %)
(As of 07/13/2020 10:47 AM ET)
Add
Compare
Today's Range
$3.87
Now: $3.99
$4.05
50-Day Range N/A
52-Week Range
$0.49
Now: $3.99
$4.45
Volume5,929 shs
Average Volume945,595 shs
Market Capitalization$93.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Read More
Navidea Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSEAMERICAN:NAVB
Previous SymbolNYSEMKT:NAVB
CUSIP63937X10
Phone+1-614-7937500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14
Market Cap$93.86 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Navidea Biopharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Navidea Biopharmaceuticals.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Navidea Biopharmaceuticals.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) released its quarterly earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter. The biopharmaceutical company earned $0.16 million during the quarter. View Navidea Biopharmaceuticals' earnings history.

What price target have analysts set for NAVB?

2 brokers have issued 1-year price targets for Navidea Biopharmaceuticals' shares. Their forecasts range from $4.00 to $6.00. On average, they anticipate Navidea Biopharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 25.3% from the stock's current price. View analysts' price targets for Navidea Biopharmaceuticals.

Has Navidea Biopharmaceuticals been receiving favorable news coverage?

News stories about NAVB stock have trended very negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Navidea Biopharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Navidea Biopharmaceuticals.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 537,300 shares, a decline of 61.9% from the June 15th total of 1,410,000 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is currently 0.3 days. Approximately 3.4% of the shares of the stock are short sold. View Navidea Biopharmaceuticals' Current Options Chain.

Who are some of Navidea Biopharmaceuticals' key competitors?

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Novavax (NVAX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Rexahn Pharmaceuticals (REXN), FuelCell Energy (FCEL), Agenus (AGEN), Catalyst Pharmaceuticals (CPRX) and AcelRx Pharmaceuticals (ACRX).

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:
  • Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 67)
  • Ms. Sharon Correia, Sr. Director of Corp. Communications

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Who are Navidea Biopharmaceuticals' major shareholders?

Navidea Biopharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.45%). Company insiders that own Navidea Biopharmaceuticals stock include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View institutional ownership trends for Navidea Biopharmaceuticals.

Which institutional investors are selling Navidea Biopharmaceuticals stock?

NAVB stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View insider buying and selling activity for Navidea Biopharmaceuticals.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $3.99.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $93.86 million. Navidea Biopharmaceuticals employs 14 workers across the globe.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is www.navidea.com.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.